Limits...
Granulocyte colony-stimulating factor-primed bone marrow: an excellent stem-cell source for transplantation in acute myelocytic leukemia and chronic myelocytic leukemia.

Li Y, Jiang M, Xu C, Chen J, Li B, Wang J, Hu J, Ning H, Chen H, Chen S, Hu L - Chin. Med. J. (2015)

Bottom Line: G-BM and G-PBSC exhibited similar survival, LFS, and TRM, but were significantly different from SS-BM (P < 0.05).There were no significant differences in leukemia relapse rates among the groups (P > 0.05).We conclude that G-BM is an excellent stem-cell source that may be preferable to G-PBSC or SS-BM in patients receiving HLA-identical sibling hematopoietic stem-cell transplantation.

View Article: PubMed Central - PubMed

Affiliation: Center of Hematopoietic Stem Cell Transplantation, 307 Hospital of People's Liberation Army, Beijing 100071, China.

ABSTRACT

Background: Steady-state bone marrow (SS-BM) and granulocyte colony-stimulating growth factor-primed BM/peripheral blood stem-cell (G-BM/G-PBSC) are the main stem-cell sources used in allogeneic hematopoietic stem-cell transplantation. Here, we evaluated the treatment effects of SS-BM and G-BM/G-PBSC in human leucocyte antigen (HLA)-identical sibling transplantation.

Methods: A total of 226 patients (acute myelogenous leukemia-complete remission 1, chronic myelogenous leukemia-chronic phase 1) received SS-BM, G-BM, or G-PBSC from an HLA-identical sibling. Clinical outcomes (graft-versus-host disease [GVHD], overall survival, transplant-related mortality [TRM], and leukemia-free survival [LFS]) were analyzed.

Results: When compared to SS-BM, G-BM gave faster recovery time to neutrophil or platelet (P < 0.05). Incidence of grade III-IV acute GVHD and extensive chronic GVHD (cGVHD) was lower than seen with SS-BM (P < 0.05) and similar to G-PBSC. Although the incidence of cGVHD in the G-BM group was similar to SS-BM, both were lower than G-PBSC (P < 0.05). G-BM and G-PBSC exhibited similar survival, LFS, and TRM, but were significantly different from SS-BM (P < 0.05). There were no significant differences in leukemia relapse rates among the groups (P > 0.05).

Conclusions: G-CSF-primed bone marrow shared the advantages of G-PBSC and SS-BM. We conclude that G-BM is an excellent stem-cell source that may be preferable to G-PBSC or SS-BM in patients receiving HLA-identical sibling hematopoietic stem-cell transplantation.

Show MeSH

Related in: MedlinePlus

Engraftment. (a) Time to absolute neutrophil count recovery above 0.5 × 109/L. (b) Time to platelets recovery above 50 × 109/L.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4837814&req=5

Figure 1: Engraftment. (a) Time to absolute neutrophil count recovery above 0.5 × 109/L. (b) Time to platelets recovery above 50 × 109/L.

Mentions: The median time to neutrophil recovery was 15 days (range, 11–26), 17 days (range, 13–31), and 25 days (range, 15–63) in the G-PBSC group, the G-BM group, and the SS-BM group, respectively [Figure 1a]. The median time to platelet recovery were 22 days (range, 12–176), 32 days (range, 15–365), and 47 days (range, 21–200) in the G-PBSC group, the G-BM group, and the SS-BM group, respectively [Figure 1b]. The time to neutrophils and platelet engraftment was significantly different among all groups (G-PBSC vs. G-BM, G-PBSC vs. SS-BM, G-BM vs. SS-BM) (P < 0.05).


Granulocyte colony-stimulating factor-primed bone marrow: an excellent stem-cell source for transplantation in acute myelocytic leukemia and chronic myelocytic leukemia.

Li Y, Jiang M, Xu C, Chen J, Li B, Wang J, Hu J, Ning H, Chen H, Chen S, Hu L - Chin. Med. J. (2015)

Engraftment. (a) Time to absolute neutrophil count recovery above 0.5 × 109/L. (b) Time to platelets recovery above 50 × 109/L.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4837814&req=5

Figure 1: Engraftment. (a) Time to absolute neutrophil count recovery above 0.5 × 109/L. (b) Time to platelets recovery above 50 × 109/L.
Mentions: The median time to neutrophil recovery was 15 days (range, 11–26), 17 days (range, 13–31), and 25 days (range, 15–63) in the G-PBSC group, the G-BM group, and the SS-BM group, respectively [Figure 1a]. The median time to platelet recovery were 22 days (range, 12–176), 32 days (range, 15–365), and 47 days (range, 21–200) in the G-PBSC group, the G-BM group, and the SS-BM group, respectively [Figure 1b]. The time to neutrophils and platelet engraftment was significantly different among all groups (G-PBSC vs. G-BM, G-PBSC vs. SS-BM, G-BM vs. SS-BM) (P < 0.05).

Bottom Line: G-BM and G-PBSC exhibited similar survival, LFS, and TRM, but were significantly different from SS-BM (P < 0.05).There were no significant differences in leukemia relapse rates among the groups (P > 0.05).We conclude that G-BM is an excellent stem-cell source that may be preferable to G-PBSC or SS-BM in patients receiving HLA-identical sibling hematopoietic stem-cell transplantation.

View Article: PubMed Central - PubMed

Affiliation: Center of Hematopoietic Stem Cell Transplantation, 307 Hospital of People's Liberation Army, Beijing 100071, China.

ABSTRACT

Background: Steady-state bone marrow (SS-BM) and granulocyte colony-stimulating growth factor-primed BM/peripheral blood stem-cell (G-BM/G-PBSC) are the main stem-cell sources used in allogeneic hematopoietic stem-cell transplantation. Here, we evaluated the treatment effects of SS-BM and G-BM/G-PBSC in human leucocyte antigen (HLA)-identical sibling transplantation.

Methods: A total of 226 patients (acute myelogenous leukemia-complete remission 1, chronic myelogenous leukemia-chronic phase 1) received SS-BM, G-BM, or G-PBSC from an HLA-identical sibling. Clinical outcomes (graft-versus-host disease [GVHD], overall survival, transplant-related mortality [TRM], and leukemia-free survival [LFS]) were analyzed.

Results: When compared to SS-BM, G-BM gave faster recovery time to neutrophil or platelet (P < 0.05). Incidence of grade III-IV acute GVHD and extensive chronic GVHD (cGVHD) was lower than seen with SS-BM (P < 0.05) and similar to G-PBSC. Although the incidence of cGVHD in the G-BM group was similar to SS-BM, both were lower than G-PBSC (P < 0.05). G-BM and G-PBSC exhibited similar survival, LFS, and TRM, but were significantly different from SS-BM (P < 0.05). There were no significant differences in leukemia relapse rates among the groups (P > 0.05).

Conclusions: G-CSF-primed bone marrow shared the advantages of G-PBSC and SS-BM. We conclude that G-BM is an excellent stem-cell source that may be preferable to G-PBSC or SS-BM in patients receiving HLA-identical sibling hematopoietic stem-cell transplantation.

Show MeSH
Related in: MedlinePlus